Technical Analysis for NSPX - Inspyr Therapeutics Inc.

Grade Last Price % Change Price Change
grade C 0.007 -12.50% -0.0010
NSPX closed down 12.5 percent on Friday, December 13, 2019, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
See historical NSPX trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Spinning Top Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -12.50%
NR7 Range Contraction -12.50%
Older signals for NSPX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Inspyr Therapeutics, Inc., formerly GenSpera, Inc., is an early-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate, renal and other cancers. Its technology platform combines a plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that targets the release of the drug within the solid tumor. Its cancer prodrugs provide a targeted therapeutic approach to a range of solid tumors. Its product candidates include Mipsagargin, G-115, G-114 and G-301. Its lead drug candidate, mipsagargin, is activated by the enzyme prostate specific membrane antigen (PSMA), which is found in prostate epithelial cells in the normal prostate, in prostate cancer cells, and in vascular endothelial cells (blood vessels) found in solid tumors. Mipsagargin is in Phase II clinical evaluation in glioblastoma patients.
Chemistry RTT Cancer Pharmaceutical Biology Solid Tumors Prostate Cancer Glioblastoma Cancer Therapeutics Solid Tumor Northwest Biotherapeutics Genspera Glutamate Carboxypeptidase Ii Prodrug Cancer

Is NSPX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 0.0316
52 Week Low 0.0015
Average Volume 470,379
200-Day Moving Average 0.0062
50-Day Moving Average 0.0100
20-Day Moving Average 0.0096
10-Day Moving Average 0.0089
Average True Range 0.0025
ADX 12.19
+DI 21.5339
-DI 21.5339
Chandelier Exit (Long, 3 ATRs ) 0.0105
Chandelier Exit (Short, 3 ATRs ) 0.0145
Upper Bollinger Band 0.0121
Lower Bollinger Band 0.0071
Percent B (%b) -0.02
BandWidth 52.0833
MACD Line -0.0008
MACD Signal Line -0.0004
MACD Histogram -0.0004
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0085
Resistance 3 (R3) 0.0087 0.0083 0.0083
Resistance 2 (R2) 0.0083 0.0080 0.0083 0.0082
Resistance 1 (R1) 0.0077 0.0077 0.0075 0.0075 0.0081
Pivot Point 0.0073 0.0073 0.0073 0.0073 0.0073
Support 1 (S1) 0.0067 0.0070 0.0065 0.0065 0.0059
Support 2 (S2) 0.0063 0.0067 0.0063 0.0058
Support 3 (S3) 0.0057 0.0063 0.0058
Support 4 (S4) 0.0055